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Role of angiotensin II in the expression and regulation of transforming
growth factor-a in obstructive nephropathy. Unilateral ureteral obstruc-
tion (UUO) leads to fibrosis of the obstructed kidney. We tested the
hypothesis that interstitial fibrosis in UUO results, at least in part, from
enhanced expression of transforming growth factor-/I (TGF-13) which in
turn is regulated by local angiotensin II (Ang II) generation. (The generic
name TGF-/3 is used to discuss properties shared by all isoforms, but
special reference to other isoforms is made when specifically needed.)
Using Northern blot and immunohistochemical analysis, we examined the
expression of TGF-/3 in rat kidneys after 24 hours (aUUO) and one week
(cUUO) of obstruction. Obstructed kidneys from both periods had
increased interstitial and perivascular TGF-/3 immunoreactivity compared
to contralateral and sham kidneys, in which immunostaining was confined
to the inner medulla. Relative abundance of all TGF-/3 mRNA isoforms
were higher in the obstructed than in contralateral and sham kidneys in
both aUUO and cUUO. Expression of TGF-13 isoforms varied according
to site (cortex vs. medulla), segment of the nephron, type of cells and
duration of the obstruction. The increase in TGF-/3 immunoreactivity and
mRNA levels in aUUO and cUUO was almost totally abolished by
pretreatment with losartan. We conclude that in UUO: (a) TGF-/3 gene
expression is increased and differentially regulated; (b) Ang II, at least
partially, mediates the overexpression of TGF-13 gene; and (c) Ang II may
play a central role in fibrogenesis in this and other models of tubulointer-
stitial disease.
Ureteral obstruction results in interstitial hypertrophy and
fibrosis of the obstructed kidney [1—4]. The magnitude of these
changes depends on the degree and duration of the impediment
to urine flow [4], but alterations occur rapidly after obstruction.
Nevertheless, the mechanism(s) by which ureteral obstruction
induces kidney fibrosis is unknown [5—8]. In general, fibrosis
develops in response to prolonged tissue injury and involves an
increased production and deposition of extracellular matrix
(ECM) [9]. Transforming growth factor beta (TGF-/3) refers to a
family of multifunctional peptides that promote ECM accumula-
tion [10]; tubules and cortical tissue from obstructed kidneys have
been shown to express higher levels of TGF-p mRNA as early as
12 hours and as late as 14 days post-obstruction [11, 12]. More-
over, inhibitors of the angiotensin I converting enzyme have been
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shown to partially reduce the relative abundance of TGF-f31
mRNA [ii].
Studies performed in our laboratory [13, 14] and by El-Dahr et
al [15] have demonstrated that acute unilateral ureteral obstruc-
tion (UUO) results in profound changes in the renal expression of
the genes that encode for the components of the RAS and in the
proteins that result from the expression of such genes. The final
result of this sequence of events is increased synthesis of angio-
tensin II (Ang II) in the obstructed kidney. Ang LI has a
stimulatory effect on TGF-13 production [16, 17] and there is
evidence that Ang II increases ECM production in the kidney [18,
19].
We examined the effect of acute (24 hours) and chronic (7 days)
UUO with and without simultaneous specific blockade of the Ang
II type-i receptor with losartan on the expression of TGF-/31, /32,
and /33 mRNAs in Wistar rat kidneys. In addition, to determine
the sites of intrarenal changes in TGF-/3 synthesis and accumula-
tion in response to UUO as well as the effect of losartan on such
response, we used immunoperoxidase staining of kidney tissue
sections with specific antibodies against TGF-f31, 132 and f3. The
use of a specific Ang II receptor antagonist, unlike Ang I converting
enzyme inhibitors which also increase bradykinin levels, permits
an analysis of the specific effect of Ang II on TGF-/3 gene
expression in this model of obstructive nephropathy. It is impor-
tant to emphasize that since ureteral obstruction affects primarily
the renal medulla, we have used immunohistochemistry to study
this part of the kidney as well as the cortex, thus providing for the
first time new information on the effects of UUO on TGF-/3
expression in this region of the kidney.
Methods
Animal handling and surgical procedures
Experiments were performed in male Wistar rats weighing 200
to 250 g (Charles River Laboratories, Raleigh, NC, USA). The
animals were housed individually in a room providing 12-hour
light and dark cycles and were maintained on standard rat chow
(Purina 5010; Purina Mills, Richmond, IN, USA) with free access
to food and water at all times prior to the experiments. After
induction of general anesthesia by the intraperitoneal injection of
ketamine (100 mg/kg body wt) and xylazine (10 mg/kg body wt),
rats were subjected to either complete UUO or sham operation.
Through a small suprapubic incision, the left distal ureter was
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identified, dissected free from its retroperitoneal site and com-
pletely occluded by a 4 to 0 silk square knot (UUO). Sham
operation consisted of a similar suprapubic incision and visualiza-
tion of the left distal ureter, but manipulation of the ureter was
not performed. The abdominal incision was closed by layers and
animals were returned to their cages when fully recovered from
anesthesia.
Experimental groups and interventions
Studies were carried out either at 24 hours (N = 12) or at 7 days
(N = 12) after UUO. A third and fourth group of sham operated
rats (N = 8 each) were used as controls. To ascertain the role of
Ang II in TGF-13 gene expression, four animals in each group
were pretreated for three days prior to and during UUO with
losartan (10 mg/kg/day), a non-peptidic, subtype 1-receptor selec-
tive Ang II antagonist, which was administered once daily by
gavage. Rats not assigned to the losartan treatment groups
received an equal amount of vehicle (distilled water) daily by
gavage. Thus, animals obstructed for 24 hours and their respective
controls received a total of five days of treatment with vehicle or
losartan, and those obstructed for one week and controls received
a total of 11 days of treatment. The term UUO is used here to
refer to the obstructed left kidney, while the right (untouched)
kidney is referred to as the contralateral kidney. All animals were
sacrificed with an intra-arterial overdose of the anesthetic (0.2 ml)
after the kidneys were perfused and harvested as described below.
Immunohistochemical studies
Antibodies. To detect kidney TGF-p proteins we utilized a
pan-specific TGF-f3 rabbit polyclonal antibody that neutralizes the
biological activity of TGF-/31, f32, and f33 (R&D Systems, Minne-
apolis, MN, USA). This antibody is referred to as a panantibody
for its ability to recognize any of these TGF-)3 isoforms. In
addition, a specific affinity-purified polyclonal neutralizing anti-
body raised in chickens and directed against human latency-
associated peptide (amino-terminal 30 amino acids, 40 kD) of the
TGF-p1 precursor, and specific goat polyclonal neutralizing anti-
bodies directed against unique sequences of porcine mature
TGF-132 and chicken isoforms were used. These isotype-specific
antibodies were also obtained from R&D Systems. In preliminary
studies, TGF-/3 localization was performed using a rabbit poly-
clonal, affinity-purified antibody that recognizes the I to 30 amino
acid residues of TGF-J31 and detects TGF-/31 and TGF-133 in the
extracellular space. The latter antibody was a gift of Dr. Michael
B. Sporn (National Cancer Institute, National Institutes of
l-Iealth, Bethesda, MD, USA); the preparation and specificity of
the latter antibody have been previously described [20]. Goat
anti-rabbit (Sigma Chemical Company, St. Louis, MO, USA) and
rabbit anti-chicken antibodies (Zymed Laboratories, South San
Francisco, CA, USA) were used as secondary antibodies.
Immunohistochemical staining. After the induction of anesthe-
sia, the abdominal aorta was catheterized, the cannula tip placed
below the left renal artery, the aorta clamped just below the celiac
trunk and the kidneys were perfused in vivo through the abdom-
inal aorta catheter with 20 ml of ice-cold 4% paraformaldehyde in
phosphate buffered saline (PBS), pH 7.4, infused at a rate of 3.1
mI/mm. Kidneys were removed and fixed in 4% paraformaldehyde
overnight at 4°C and then processed for paraffin embedment.
TGF-p isotypes were localized in 7-micron thick tissue sections
using the Zymed histostain kit. To block endogenous peroxidase,
sections were pretreated with hydrogen peroxide (0.3% in meth-
anol) for 10 minutes at room temperature. In addition, tissue
sections were digested with hyaluronidase (0.0 1% in 0.1 M sodium
acetate, pH 5.5, 0.15 M sodium chloride, Calbiochem-Behring
Corp., La Jolla, CA, USA) for 15 minutes at room temperature
prior to antibody labeling. Sections were blocked with 10% goat
serum for 10 minutes, then incubated with primary antibody for 30
minutes at 37°C. The pan-specific TGF-13 antibody was diluted
1:50 and the TGF-f31 to 3 isoform-specific antibodies were diluted
1:40 in TBS (135 m sodium chloride, 24 mi Tris, 2.6 ifiM
potassium chloride) containing 1% bovine serum albumin (BSA).
The sections were washed three times for three minutes each in
TBS + 0.1% BSA and then incubated with biotinylated secondary
goat anti-rabbit or rabbit anti-chicken antibody (Zymed) for 10
minutes at room temperature, followed by washing and a 10
minute incubation with an avidin-biotin-peroxidase complex
(Zymed). After further washing the peroxidase enzyme was
detected with the aminoethyl carbazole substrate which yields a
red reaction product. All sections were counterstained with
Mayer's hematoxylin and mounted first with a thin layer of
aqueous mounting media (Crystal Mount, Fisher Scientific, Pitts-
burgh, PA, USA), quickly dipped in xylenes and subsequently
mounted in Permount (Fisher Scientific). As a negative control,
nonimmune rabbit IgG was used instead of the primary antibody
at the same concentrations as the primary antibodies. Tissue
staining intensity was rated as trace (tr, 0.5), mild (1), moderate
(2), or intense (3); if no staining was seen a value of zero was
assigned. The staining rating was judged subjectively and inde-
pendently by three of the investigators. All immunohistochemical
comparisons were done among similarly handled tissue. Micro-
graphs were obtained using an Olympus-Vanox AHBT3 micro-
scope. Because tissue preparation was done in two different
laboratories (Atlanta and Bethesda) the coloration of various
micrographs varied.
RNA purification and Northern hybridization analysis
Rats were anesthetized as described above, the kidneys were
rapidly removed, decapsulated, snap frozen in liquid nitrogen and
stored at —70°C until ribonucleic acid isolation was performed.
Whole kidney RNA was extracted from tissue homogenates using
guanidinium isothiocyanate by the method of Chirgwin et al [21].
A 260/280 nm wavelength absorbance ratio> 1.8 was considered
an appropriate RNA preparation. A total of 20 sg of RNA was
run on agarose gels containing 2.2 M formaldehyde. RNA was
transferred by capillary blotting to Zeta-probe blotting mem-
branes (Bio-Rad Laboratories, Richmond, CA, USA) using stan-
dard procedures. Blots were washed in 6 X SSC for five minutes,
then baked under vacuum for one hour at 80°C.
TGF-j3 cDNAs
The TGF-J3 cDNAs were obtained as a courtesy of Dr. Su Wen
Qian (Laboratory of Chemoprevention, National Cancer Insti-
tute, National Institutes of Health). Rat TGF-j31 eDNA was
originally cloned into the EcoRI site of the plasmid pBluescript II
KS+ vector. The insert was a 986 bp and was linearized with XbaI;
a full-length antisense cRNA probe was transcribed from the T7
promoter site using T3 polymerase (Fisher Scientific). Mouse
TGF-f32 cDNA was cloned in the pBluescript KSII at the SmaI
site. The insert was 1120 bp and was subjected to endonuclease
digestion with XbaI; transcription from the T7 promoter site using
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T3 polymerase yielded a full-length antisense cRNA. Mouse of comparable specific activities were used. Purified riboprobes
TGF-/33 eDNA was cloned in the pBluescript KS I at the EcoRI were stored in 75% ethanol at —20°C.
site; it was 1231 bp and was linearized with XbaI; transcription
from the T7 promoter site using T3 polymerase yielded a full- Prehybridization and hybridization
length antisense cRNA. Blots were prehybridized for six hours at 60°C with hybridiza-
tion buffer [50% formamide, 5 X SSC (1 X SSC: 0.15 M NaCI,
0.015 M sodium citrate, pH 7], 8X Denhardt's solution, 1 mrvi
EDTA, 0.1% sodium pyrophosphate, and 0.5% SDS, 200 ig/ml
denatured salmon sperm DNAI. A mixture of 0.5 to 1.0 >< io
CPM probe in 0.2 ml hybridization buffer was heated to 85°C for
five minutes, added to 4 ml hybridization buffer and 1 ml 50%
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Fig. 1. Kidney TGF-13 immunohistochemicat staining. A pan-specific rabbit polyclonal antibody directed against TGF-131, TGF-132 and TGF-133 was used
as primary antibody. A and B (50X) show cortical views of kidneys obstructed for 24 hours where cytokine immunoreactivity is seen in the interstitium,
JGA (A, arrow), around tubule epithelial cells (arrowhead), Bowman's capsule (white arrow), perivascular tissue (B, arrow), and, note the intense
staining along the entire length of the afferent arteriole (aa) and the interlobular artery (panel B, IA). In contrast, immunostaining in the JGA is mild
in the contralateral (C, 50x) and absent in a sham kidney (D, 40X). E (40><) and F (50x) show cortical and medullary views of kidneys obstructed for
7 days. As can be seen, TGF-j3 interstitial immunoreactivity remains intense in both areas of the kidney.
Preparation of riboprobes
Riboprobes were transcribed using 0.5 to 1 sg template eDNA
and labeled using 32P-UTP (3000 Ci/mmol, Amersham, Arlington
Heights, IL, USA). Full-length antisense transcripts were used for
hybridization. Within individual experiments, labeled riboprobes
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Fig. 2. Kidney TGF-J3 immunohistochemical staining in rats with acute (24 hr) UUO. A pan-specific rabbit polyclonal antibody directed against TGF-131,
TGF-132 and TGF-133 in the extracellular space was used as primary antibody. Top panels show cortex (A) and medulla (B) (notice that the papilla is
markedly atrophic after as little as 24 hours of UUO) of obstructed kidneys; middle panels are representative of contralateral kidneys showing absent
perivascular (C, cortex) cytokinc immunoreactivity and significant inner medullary staining (0, papilla). Bottom panels show sham kidneys exhibiting
no immunostaining in the cortex (E) and faint staining in the outer medulla (F). Note the strong perivascular immunostaining in the cortex (A) and outer
medulla (B) of obstructed kidneys (40X).
dextran sulfate and thoroughly mixed. Hybridization was carried neutralized by immersion in 0.02 M Tris-HC1 (pH 8.0) + 0.1 x
out overnight (16 to 18 hr) at 60°C. Membranes were washed for SSC + 0.5% SDS for 45 to 60 minutes, they were ready to be
30 minutes, first in 2 x SSC + 0.2% SDS at 65°C and finally in 0.2 reprobed. Prehybridization and hybridization for GAPDH mRNA
X SSC + 0.2% SDS at 70°C. Dry blots were exposed overnight were performed as described above.
with intensifying screen on Kodak Tri-X-OMAT film.
mRNA quantification
Membrane reprobing Hybridization signals on individual autoradiograms were quan-
For reprobing with glyceraldehyde-3-phosphate dehydrogenase tified by densitometry. Autoradiographs were scanned with a MD
(GAPDH) cRNA, membranes that had been previously hybrid- ImageQuant 228 densitometer (Molecular Dynamics, Sunnyvale,
ized were washed in 0.1 N NaOH for 30 minutes at room CA, USA), using software version 3.22. GAPDH mRNA band
temperature. A Geiger counter was used to ensure that there was absorbance in each Northern blot was used as a standard for
no detectable residual radioactivity. After the membranes were normalizing the absorbance of TGF-f3 mRNA bands. TGF-f3
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Fig. 3. Kidney TGF-13 immunoreactivity in rats with chronic UUO. Immunohistochemical staining was performed using a pan-antibody as described in
Figures 1 and 2. Panels are set up as in Figure 2. In the obstructed kidneys, the increased perivascular TGF-f3 staining (A) persisted, but its interstitial
medullary (B) content was higher than in acute UUO. In the contralateral kidney (C), as was the case with acute UUO, there was no perivascular
staining, however, its papillaiy expression (D) has virtually disappeared. In contrast, sham kidneys perivascular and medullary immunoreactivities (E and
F) are indistinguishable from that of acute shams (Fig. 2 E, F), and similar to that of the contralateral kidney shown in panels C and D (40X).
mRNAs were quantified by measuring the ratio of optical absor- and UUO + losartan) of acute and chronic UUO. Data are
bance of each TGF-f3 mRNA band to that of GAPDH mRNA. expressed as mean standard errors (SE). One way analysis of
Results are expressed as relative densities. In addition, post- variance (ANOVA) was used to determine the significance of the
separation ethidium bromide staining was used for RNA detec- differences among groups. A value of P < 0.05 was accepted as
tion and the 28S and 18S ribosomal RNA bands were visualized by significant.
transillumination with ultraviolet light (at about 300 nm) and
recorded in Polaroid film. We have previously shown that acute Results
UUO does not alter GAPDH mRNA expression [13, 14]. .Immunohistochemical studies
Statistical analysis TGF-13 localization using the panantibody. Figures 1, 2, and 6
Data from each kidney (either tissue staining scores or relative (acute UUO) and Figures 1 and 3 (chronic UUO) are represen-
density ratios) were pooled and groups of left and right kidneys tative of the overall findings. Nonimmune rabbit serum did not
were formed within each group (sham, sham + losartan, UUO, stain any of the sections (not shown). After 24 hours of UUO,
1238 Pimentel et al: TGF-f3 in obstructive nephropathy
Fig. 4. Effect of losartan treatment on kidney TGF-J3 immunoreactivity in UUO. A pan-specific rabbit polyclonal antibody against TGF-p1, TGF-f32 and
TGF-$3 isoforms was used. Acute untreated (A) and treated (C), and chronic untreatcd (B) and treated (D) UUO kidneys are shown. The abolition
of perivascular staining in both losartan treated models can easily be appreciated (50X).
obstructed kidneys exhibited a dramatic increase in TGF-3 im-
munoreactivity in the interstitium, primarily around blood vessels
(usually in the adventitia and connective tissue; Figs. 1B, 2A and
oA). In addition, as can be seen in Figure 1B, there was a marked
increase in staining in interlobular arteries, afferent arterioles and
JGAs as compared to the contralateral (Fig. 1C), and sham
kidneys (Fig. 1D). It should be noted that in contrast to the
discrete localization of TGF-/3 immunoreactivity in the JGA of
contralateral kidneys (Fig. 1C), in acute UUO kidneys, not only
was the immunoreaetivity increased in JGAs, but it was seen
throughout the entire length of the afferent arterioles and the
interlobular arteries (Fig. 1B). There were no differences in
perivaseular staining between the contralateral and sham kidneys
(Fig. 2 C, E). Likewise, medullary interstitial TGF-j3 immunore-
activity was more abundant in obstructed than in contralateral and
sham kidneys (Fig. 2 B, D, F); moderate medullary TGF-f3
immunoreactivity was seen in the contralateral but not in sham
kidneys (Fig. 2 D, F). After seven days of UUO, perivaseular (Fig.
3A), and medullary (Figs. iF and 3B) TGF-/3 immunoreactivity
remained prominent in the obstructed kidneys compared to
contralateral (Fig. 3 C, D) and shams (Fig. 3 E, F); of note,
expression in the papilla (seen in acute UUO, Fig. 2D) virtually
disappeared as the papilla became atrophic. In the contralateral
kidneys, perivascular staining was absent and medullary TGF-13
immunoreactivity was indistinguishable from that of sham kidneys
(Fig. 3 C, D, F). TGF-/3 interstitial immunoreactivity, both cortical
and medullary, was higher in chronic than in acute UUO kidneys
(Fig. 1 A and E are representative of the cortex), The intensity of
staining was trace to mild in all sham and eontralateral kidneys
whether acute or chronic, and there were no clear-cut or consis-
tent differences among these groups. Consistently in UUO kid-
neys, all staining, both perivascular and medullary was confined to
the interstitium and was focal, with only some areas of the kidney
involved.
Furthermore, acute and chronic UUO kidneys showed TGF-j3
immunoreactivity in Bowman's capsule (Fig. 1A), pelvic and
ureteral transitional epithelium, and around or within tubule
epithelial cells (Fig. 1 A, F). Although TGF-/3 was mostly and
almost exclusively expressed in the papillary region (inner me-
dulla) in the contralateral kidneys (Fig. 2D), mild immunoreac-
tivity was seen in JGAs (Fig. IC), tubule epithelial cells and
smooth muscle cells (not shown). By contrast, sham kidneys
exhibited faint TGF-/3 immunostaining only in JGAs and medul-
lary interstitium. Thus, the most striking distinction in TGF-/3
expression induced by acute UUO was the appearance and/or
enhancement of immunoreactivity in perivaseular regions, JGAs,
Bowman's capsule, and the outer medullary interstitium.
In summary, the panantibody gave strong immunoreactivity in
JGAs, afferent arterioles and interlobular arteries, perivascular
and peritubule interstitial tissue, vasa recta, and medulla in
24-hour obstructed kidneys. In sham and contralateral kidneys,
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however, only the JGA and the inner medulla stained signifi-
cantly. Similar results were obtained in 7 day UUO, however, the
increase in TGF-/3 immunoreactivity in the perivascular regions
was more prominent in kidneys obstructed for 24 hours than in
those obstructed for 7 days. Conversely, the medullary interstitial
TGF-p immunoreactivity in chronically obstructed kidneys was
higher than that observed in the acutely obstructed ones.
Effect of losartan treatment. Losartan treatment for three days
before and during obstruction (Fig. 4) consistently abolished the
increased interstitial (not shown) and perivascular TGF-f3 staining
in both acute (Fig. 4 A, C) and chronic UUO (Fig. 4 B, D). In
acute UUO (N = 6), perivascular staining scores in the untreated
obstructed kidneys were 2.7 0.2 versus 1.7 0.3 in the
losartan-treated obstructed ones (P < 0.04), and interstitial
staining scores were 2.7 0.2 versus 1.3 0.3, respectively (P <
0.01). In chronic UUO (N = 6), perivascular staining scores in the
untreated obstructed kidneys were 1.5 0.3 versus 0.5 0.01 in
the losartan-treated obstructed ones (N = 4,P < 0.04); interstitial
staining scores were 2.2 0.2 versus 1.2 0.01, respectively (P <
0.04). In both acute and chronic contralateral and sham kidneys
(N = 3) no differences in interstitial and vascular staining scores
were seen after losartan treatment.
The results of the TGF-/3 immunohistochemical analysis using
the panantibody in acute and chronic UUO with and without
losartan treatment are summarized in Table 1. Tissue staining
intensity was rated as trace (tr, 0.5), mild (1), moderate (2), or
intense (3) as described above, and, if no staining was seen a value
of zero was assigned. In 24 hour UUO and contralateral kidneys
(N = 6 each), interstitial staining scores were 2.6 0.2 versus 1.3
0.2, respectively (P < 0.001), and vascular staining scores were
2.6 0.2 versus 0.7 0.1, respectively (P < 0.001). There were no
differences in interstitial (0.8 0.2 vs. 1.2 0.4; P = NS) or
vascular (0.8 0.2 vs. 0.5 0.1; P = NS) staining scores between
left and right kidneys in shams rats or between contralateral and
sham kidneys. In 7 day UUO and contralateral kidneys (N = 6
each), interstitial staining scores were 2.2 0.2 versus 0.7 0.1,
respectively (P < 0.001), and vascular staining scores were 1.5
0.3 versus 0.5 0.01, (P = 0.01). No differences in interstitial (1
0.01 vs. 0.7 0.2; P = NS) or vascular staining scores (0.5
0.01 vs. 0.5 0.01; P = NS) between left and right kidneys in
shams rats (N = 3) or between contralateral and sham kidneys
were seen. The data reveal that UUO invariably increases TGF-f3
immunoreactivity in the obstructed as compared to contralateral
and sham kidneys in both acute and chronic UUO.
TGF-/3 localization using isoform-specific antibodies. Figures 5
and 6 are representative of the overall results obtained using
specific antibodies against TGF-/31, 132 and 133 in acute UUO.
TGF-131 immunoreactivity in UUO kidneys (N = 2) was seen
mainly in JGAs and peritubule capillaries (Fig. 5 A, B), but also
within tubule epithelial cells (not shown) and interstitial mono-
nuclear cells (Fig. 6C). On the other hand, faint or no immunos-
taming was seen in contralateral and sham kidneys (N = 2, not
shown).
TGF-/32 immunoreactivity in the UUO kidneys (N = 2) was
marked in blood vessels and tubular epithelium (Figs. 5C and 6D,
respectively); it was also prominent in JGAs (not shown) and
ureteral transitional epithelium (Fig. 5D). TGF-f32 immunoreac-
tivity was faint in contralateral and sham kidneys (N = 2, not
shown), and there were no differences in intensity of staining in
contralateral compared to sham kidneys. Moreover, its distribu-
Table 1. Summary of kidney TGF-/3 immunohistochemical analysis in
rats with acute and chronic UUO with and without losartan treatment.
Time
24-hr
Kidney
UUO
Staininga Kidney
interstitial vascular Control
Staininga
interstitial vascular
1L
2L
3L
4L
5L
6L
Sham
1L
2L
3L
2
2
3
3
3
3
1
1
tr
3 1R
3 2R
3 3R
3 4R
2 5R
2 6R
Sham
1 1R
tr 2R
1 3R
1
1
1
2
1
2
1
2
tr
1
1
1
tr
tr
tr
tr
tr
tr
1L
2L
3L
Sham
1
2
1
1
Losartan treated
2 1R
2 2R
1 3R
1 Sham
2
1
tr
—
tr
tr
tr
—
7-days 1L
2L
3L
4L
5L
6L
Sham
1L
2L
3L
3
2
2
2
2
2
1
1
1
1 1R
1 2R
1 3R
3 4R
2 SR
1 6R
Sham
tr 1R
tr 2R
tr 3R
tr
1
1
tr
tr
1
tr
1
tr
tr
tr
tr
tr
tr
tr
tr
tr
tr
1L
2L
3L
Sham
1
2
tr
—
Losartan treated
tr 1R
tr 2R
tr 3R
tr Sham
1
tr
tr
—
tr
tr
tr
—
a Tissue staining is rated as absent (—), trace (tr), mild (1), moderate (2),
and intense (3). Interstitial staining includes both cortex and medulla.
Vascular staining refers to perivascular immunoreactivity. UUO is the
obstructed left (L) kidney; Control refers to the matching intact right (R)
kidney. The numbers on the kidney columns refer to the rat number code.
tion was discrete, and limited to tubule epithelial cells, vasa recta
and papillary interstitium, with faint staining of the JGA.
TGF-133 immunoreactivity in the UUO kidneys (N = 2) was
markedly increased in vessels and tubules (Fig. SE), but only
slightly in the perivascular tissue and cortical interstitium. There
was marked expression of TGF-133 immunoreactivity in the tran-
sitional epithelium of the renal pelvis (Fig. 5F) and in the
interstitium and collecting ducts of the blunted papillae (Fig. 6E).
Conversely, the contralateral and sham kidneys (N = 2, not
shown) showed similar mild staining patterns, with significant
TGF-f33 immunoreactivity in tubules, including descending and
ascending limbs of Henle, but none in vessels or glomeruli.
In kidneys obstructed for 24 hours (but not in contralateral or
shams), we consistently detected mononuclear cells in the inter-
stitial space, many of which exhibited TGF-f31 immunoreactivity
(Fig. 6C). We did not detect TGF-/31 immunoreactivity in inter-
stitial mononuclear cells in losartan-treated UUO kidneys,
whether acute or chronic (not shown). Table 2 summarizes the
major immunostaining findings using specific antibodies against
each TGF-p isoform.
• D
.11I'
Ui
4v
B
C.
S a
aS
7.
p
DY
V
t't
'.dç
1240 Pimentel et al: TGF-13 in obstructive nephropathy
Fig. 5. Kidney immunoreactive TGF-13 isoforms in acute UUO. Specific antibodies against each cytokine isotype were used. TGF-f31 immunostaining is
detected in the JGA (A, arrow), and peritubular capillaries (B, arrow). TGF-f32 immunoreactivity (C and D) can be seen in tubule epithelium (arrow),
vascular smooth muscle cells (arrowheads), and ureteral transitional epithelium (D). TGF-133 immunostaining is seen in tubular epithelium (arrowhead),
vascular smooth muscle cells (E, arrow), and ureteral transitional epithelium (F) (50x).
TGF-f3 mRWAs expression
Figures 7 to 9 show representative Northern blots of whole
kidney RNA in rats with 24 hours of UUO. Relative abundance is
always related to GAPDH, but we also show that loading was
equal in all lanes. Northern blot analysis of total RNA isolated
from whole kidneys of rats with 24 hour and 7 day UUO revealed
the presence of a single 2.5 kb mRNA transcript for TGF-131 (Fig.
7). Sham and contralateral kidneys showed similar relative abun-
dance of TGF-f31 mRNA in acute (0.4 0.05 vs. 0.4 0.04,
respectively; P = NS,N = 6) and chronic UUO (0.4 0.03 vs. 0.5
0.04, respectively; P = NS, N = 6). No systematic variation was
noted in the relative amount of TGF-131 mRNA in losartan-
treated sham and contralateral kidneys either in acute (0.4 0.02
vs. 0.4 0.03, respectively; P = NS, N = 6) nor in chronic UUO
(0.5 0.02 vs. 0.4 0.04, respectively; P = NS, N = 6).
Correction for GAPDH revealed that relative abundance of
TGF-/31 mRNA in acute UUO kidneys (Fig. 1OA) was higher than
contralateral and sham kidneys (0.6 0.06; 47 10% increase vs.
contralateral, P < 0.05, N = 6). In chronic UUO (Fig. lOB),
TGF-/31 mRNA relative abundance in the UUO kidneys was
threefold higher than the contralateral kidneys (1.3 0.09; 227
56% increase, P < 0.001, N = 6). Losartan treatment of the
animals for three days before and during acute UUO (Figs. 7 and
1OA) consistently and totally abolished the obstructed kidney
increase in TGF-f31 mRNA relative amount (0.4 0.07, P < 0.05,
N = 6), and reduced the obstructed kidney TGF-p1 mRNA
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Fig. 6. Immunolocalization of kidney TGF-p in acute UUO. A and B. Immunoperoxidase staining for TGF-13 using a pan-antibody that detects the three
major isoforms f3 . Perivascular immunoreactivity is located to the adventitia and perivascular connective tissue (A, the asterisk indicates the vascular
lumen); in the outer medulla, staining is found primarily in the peritubular interstitium (B). As can be seen, TGF-/3 immunostaining is associated with
characteristic interstitial cells (A and B, arrows; magnification A 440X; B 630x). C. Immunoreactive TGF-p1 surrounds numerous interstitial
mononuclear cells, some of which have polymorphonuclear cell morphology (arrow) and others resemble lymphocytes (arrowheads, 675X). D. Epithelial
tubular cells depicting TGF-j32 immunoreactivity (arrowheads, 330x). E. Papillary tip delineating TGF-/33 immunolocalization in collecting ducts(asterisks) and interstitium (330x). Reproduction of this figure in color was supported by Merck Pharmaceuticals.
relative levels by 56% in chronic UUO (0.7 0.05; P < 0.002, N Figures 8 and 9, respectively, and in Figure bA. Single mRNA
= 6; Fig. lOB), transcripts (4.5 and 5.5 kb for TGF-f32 and TGF-f33, respectively)
Northern blot analysis for TGF-132 and TGF-f33 mRNAs in were detected. Sham and contralateral kidneys TGF-f32 (0.4
acute UUO with and without losartan treatment is shown in 0.04 vs. 0.5 0.05 respectively, P = NS, N = 4) and TGF-p3
1 2 3 4 5 6 7 8
2.4kb — TGF
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Table 2. TGF-f3 isoforms immunoreactivity" in rat kidneys obstructed
for 24-hr.
Cortex Medulla
_________ ______ Ureter Infiltrating
mononuclear
Antibody JGA BC PT PV Outer Papilla TE cells
TGF-/31 3 — 2 3 3 2 — 3
TGF-/32 1 — 3 3 2 2 3
TGF-/33 — 2 3 3 2 2 3 —
a Tissue staining rating as in Table 1. JGA, juxtaglomerular apparatus;
BC, Bowman's capsule; PT, peritubular and tubular; PV, perivascular and
vascular; TE, transitional epithelium.
mRNAs (0.5 0.09 vs. 0.5 0,1, respectively, P NS, N = 6)
ratios of absorbance were similar and did not differ after losartan
treatment, Obstructed kidneys displayed a significant increase in
the relative abundance of TGF-f32 mRNA compared to the
contralateral (3.5 0.1; 326 111% increase, P < 0.001, N = 4)
and sham kidneys. The enhanced TGF-f32 mRNA expression in
the obstructed kidneys was markedly blunted by pretreating the
animals with losartan (2.0 0.1, —40%; P < 0.002, N = 4).
TGF-/33 mRNA expression was also higher in UUO compared
with contralateral kidneys (1.8 0.1; 313 54% increase, P <
0.001, N 6) and losartan treatment resulted in a 53% decrease
in the expression of TGF-/33 mRNA (1.1 0.09; P < 0.002, N =
6).
Figure lOB shows the densitometry results of Northern blot
analysis of TGF-132 and TGF-133 mRNA expression in chronic
UUO with and without losartan treatment. TGF-132 mRNA
expression in sham and contralateral kidneys did not differ (1.8
0.08 vs. 1.6 0.07, P = NS,N = 6). TGF-132 mRNA expression in
UUO was higher than in contralateral kidneys by 52% (3.3 0.1,
P < 0.05, N = 6). Expression of this isoform was completely
blunted by treating the rats with losartan (2.1 0.1, P < 0.05, N
= 6). TGF-/33 mRNA relative abundance was also increased in
obstructed kidneys (4.6 0.1) compared to the contralateral ones
(1.2 0.05 vs. 318 45% increase, P < 0.001, N = 6). Treatment
of the animals with losartan totally abolished the increase in
TGF-/33 mRNA in the obstructed kidneys (1.2 0.09 vs. 4.6 0.2,
P < 0,01, N = 6) with no significant effect on the contralateral
ones.
In summary (Fig. 10), acute UUO was associated with predom-
inantly increased TGF-/32 and TGF-f33 mRNAs expression in the
UUO kidneys, and lesser relative abundance of TGF-/31 mRNA;
losartan treatment totally blunted the increase in the latter but not
of the /32 and 133 mRNAs. Conversely, chronic UUO showed
higher relative amount of TGF-f31 and TGF-f33 mRNAs with
lower levels of mRNA for TGF-/32; losartan treatment resulted in
partial reduction in the increased TGF-f31 mRNA and complete
reversal in the increased /32 and /33 mRNAs relative abundance.
Discussion
TGF-/3 increases the production of many ECM proteins such as
collagen, fibronectin and proteoglycans in kidney fibroblasts and
epithelial cell lines [22—25]. This cytokine also inhibits ECM
degradation by increasing the production of proteinase inhibitors
and decreasing the expression of degradative enzymes such as
collagenase [26, 271. Furthermore, TGF-/3 is a chemoattractant
for fibroblasts and mononuclear cells and stimulates their prolif-
eration [28, 29]. In addition, there is evidence that a natural
Fig. 7. Northern blot analysis of TGF-/31 mRNA in four rats with 24 hour
UUO. This autoradiograph is representative of the whole experimental
series. Each lane represents 20 jsg of RNA from each kidney of each rat.
Lanes I to 4 represent the contralateral kidneys and lanes 5 to 8 represent
the obstructed kidneys; losartan-treated kidneys are in lanes 4 and 8 (other
lanes are untreated kidneys). Messenger RNA transcript size is indicated
on the left of the Figure. The negative effect of losartan on TGF-/31
mRNA expression in the UUO kidney is clear-cut. The 18S and 28S
ribosomal RNA transcripts detected by ethidium bromide staining is
shown below the autoradiograph to indicate equality of loading and
integrity of RNA. Hybridization of the blot to a GAPDH probe was used
to verify equivalent loading and transfer of RNA (not shown).
inhibitor of TGF-f3 protects against fibrosis in experimental
kidney disease [30]. Thus, evidence has accumulated that estab-
lishes TGF-j3 as a major regulator of ECM deposition and
fibrogenesis. The results of the present experiments suggest that
TGF-/3 plays a major role in the renal injury that results from
UUO.
Both at 24 hours and 7 days after UUO we observed enhanced
expression of TGF-f31, /2, and /33 in the obstructed kidneys as
compared to the contralateral and sham kidneys. In obstructed
kidneys, the levels of TGF-/3 isoforms mRNAs were reduced by
losartan, suggesting that Ang II regulates stimulated activity of the
cytokine in UUO. It is not clear from these studies, however, if
Ang II per se is a mediator of the process of fibrogenesis in the
renal medulla following obstruction of the urinary tract, While
TGF-131 is the isoform most implicated in fibrosis, our experi-
ments show that UUO leads to different degrees and sites of
expression of all three TGF-/3 isoforms and that it is possible that
all are involved in fibrogenesis in UUO. In addition, our results
suggest that the expression of TGF-/3 isotypes in UUO is time-
dependent, with TGF-f32 being markedly increased in acute, but
with increases in TGF-/31 and 133 being predominant in chronic
UUO.
We have previously shown that acute UUO is associated with a
marked increase in medullary renin mRNA, endothelial ACE
mRNA, and perivascular angiotensinogen mRNA expression in
the obstructed kidney [13]. Therefore, our finding that losartan
regulates the expression of TGF-/3 mRNA and modulates the
cellular site of localization of its isoforms in the medulla, strongly
suggests that Ang II is responsible for the expression of at least
one factor (TGF-/3) mediating the process of fibrogenesis in this
model of obstructive nephropathy.
Walton and colleagues [7] have clearly shown an increase in
kidney TGF-/31 mRNA expression 48 hours following UUO in
TGF-132
1 2 3 4 5
4.5 kb- —
1.3 kb-
6 7 8
GAPDH
Pimentel et al: TGF-f3 in obstructive nephropathy 1243
Fig. 8. Representative Northern blot analysis of
TGF-/32 mRNA in acute UUO. Twenty
micrograms of total RNA were loaded in each
lane. Lanes I through 4 represent RNA (each
extracted from one kidney of a different
animal) from contralateral kidneys; lanes 5
through 8 represent RNA from obstructed
kidneys; losartan-treated kidneys are in lanes 3,
4, 7, and 8. Untreated kidneys are in lanes 1, 2,
5, and 6. Messenger RNAs transcripts sizes are
indicated on the left of the Figure. Top panel:
TGF-f32 mRNA. Middle panel shows GAPDH
probe hybridization to the same blot. Bottom
panel shows ethidium bromide staining
demonstrating the 18S and 28S ribosomal RNA
transcripts. Note that losartan reduced TGF-j32
mRNA expression in UUO kidneys but had no
notable effect on the contralateral ones.
rats. This effect of UUO was corroborated by Diamond and his
collaborators [12] who observed a 2.5-fold increase in relative
(corrected for GAPDH) abundance for TGF-131 mRNA in ob-
structed rat kidneys compared to shams 12 hours after UUO; the
increase in the relative abundance of the transcript persisted in
kidneys obstructed for 96 hours. Kaneto, Morrissey and Klahr
[11], using polymerase chain reaction-reverse transcription anal-
ysis (PCR-RT), were unable to demonstrate a rise in TGF-f31
mRNA levels before three days after ureteral obstruction; how-
ever, the increased TGF-j31 mRNA expression persisted for at
least 14 days. These investigators [11] attributed the failure to
observe earlier changes in gene expression to "instability of the
message."
Of the studies described above, only those of Diamond et al [12]
provided proof that the enhanced gene expression was accompa-
nied by transcription and translation into TGF-3 proteins. Using
a rabbit polyclonal anti-TGF-1 antibody, these investigators
detected immunostaining in peritubular cells, some of which had
macrophage nuclear morphology, but only in kidneys obstructed
for 48 hours. We show here that TGF-/31 mRNA levels are also
increased at 24 hours as well as at 7 days post-obstruction, and
for the first time, that concomitantly TGF-p2 and TGF-3
mRNA levels are also increased. Moreover, we offer proof that in
kidneys obstructed for 24 hours, this enhanced expression is
accompanied by increased synthesis of the proteins as shown by
increased TGF-/3 isotype immunoreactivity in the interstitium of
the cortex, outer medulla, and papilla, the juxtaglomerular appa-
ratus, perivascular space of medullary medium-sized vessels,
peritubular capillaries, tubular epithelial cells, and transitional
epithelium.
Pretreatment of the animals with losartan led to a major
modification of the TGF-13 mRNAs coding for the various iso-
forms. Losartan abolished the elevation in TGF-p1 mRNA, and
markedly reduced TGF-p2 and TGF-/33 mRNA levels at 24 hours.
In chronic UUO, losartan abolished the increase in TGF-f32 and
TGF-135 mRNAs, and reduced TGF-j31 mRNA by approximately
50%. Tissue TGF-p isoforms immunoreactivity distribution after
1 and 7 days was also dramatically modified by losartan. Thus,
reduction of TGF-13 isoforms mRNAs was accompanied by dimin-
ished protein immunoreactivity. This is evidence that the TGF-p
isoforms are differentially regulated depending on duration of
UUO, the region of the kidney, the segment of the nephron, and
the type of cell in which the isoforms are expressed. Several recent
studies have indicated that expression of the various TGF-/3
mRNAs are differentially regulated in other cells such as PC-3
prostate carcinoma cells [31] and rat interstitial cells [32].
Whether these distinct patterns of TGF-/3 isotypes mRNA expres-
sion in UUO are related to differences in the degree of stimula-
tion of the RAS or independent changes in TGF-p gene expres-
sion and/or induction of other fibrogenic cytokine(s) remains to
be studied.
We chose two specific periods of UUO duration because at 24
hours the systemic plasma renin activity (PRA) is back to control
or normal levels, while at 7 days PRA is again elevated above
normal values [13—15]. This suggests, although it does not prove,
that in addition to the classical endocrine route, paracrine and/or
autocrine effects are most likely at work in the regulation of
TGF-/31 by Ang II in UUO at least at 24 hours. In the present
study, we demonstrate that TGF-13 immunostaining in JGAs is
more intense in obstructed than in contralateral or sham kidneys.
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Fig. 9. Representative Northern blot analysis of TGF-131 mRNA in acute
UUO. Twenty micrograms of total RNA were loaded in each lane. Lanes
1 through 4 represent RNA (each extracted from one kidney of a different
animal) from contralateral kidneys; lanes 5 through 8 represent RNA
from obstructed kidneys; losartan-treated kidneys are in lanes 3, 4, 7, and
8. Untreated kidneys are in lanes 1, 2, 5, and 6. Messenger RNAs
transcripts sizes are indicated on the left margin. Top panel, TGF-133
mRNA; middle panel, GAPDH reprobing to the same membrane is
shown; bottom panel shows ethidium bromide staining detecting the 18S
and 28S ribosomal RNA transcripts. Note that losartan reduced the
expression of TGF-p3 mRNA in UUO kidneys but had no significant
effect on the contralateral ones.
Also, TGF-pI and TGF-/32 have been colocalized with renin in the
JGA [33], and the relative abundance of the message for TGF-j32
(but not for TGF-f31) and for renin in the JGA, as well as plasma
renin activity, rise after dehydration in mice [34]. Moreover,
TGF-p1 and TGF/32 in picomolar concentrations are very potent
renin secretagogues [351. We have consistently observed that
plasma renin activity after UUO rises early (1 hr) and remains
elevated for approximately 12 hours, and becomes normal at 24
hours only to rise again at 7 days. TGF-/32 mRNA rose less at 24
hours and more at seven days, while TGF-131 mRNA followed the
reverse pattern. This suggests that the observed "bimodal" in-
crease in plasma renin activity could be related to the differential
regulation of the TGF-J3 isoforms mRNAs which influence renin
secretion in UUO. Studies specifically designed to test this
hypothesis, however, are needed.
Diamond and colleagues [12] have found that renal cortical
mononuclear cell infiltration temporally coincides with increased
cortical expression of TGF-f31 in Sprague-Dawley rats. In addi-
tion, enhanced expression of the monocyte chemoattractant pep-
Fig. 10. Densitometiy analysis of Northern blot autoradiographs for TGF-13
isoforms mRbJAs in acute (A) and chronic UUO (B). The ordinate axis
values represent the percent increase in relative density ratios (normalized
with GAPDH) when the UUO kidney data are compared with the
respective contralateral group. Since the latter groups' values (contralat-
eral kidneys with and without losartan treatment) neither differ among
each other nor from shams, they are expressed as a 100% value indicated
by a horizontal line in the plots. *p < 0.05 for comparisons between the
untreated UUO kidneys and the losartan (Los) treated ones; N = 6 in all
groups except the acute UUO TGF-j32 group in which N = 4. These data
should not be interpreted as representing the relative abundance of each
isoform. Under most circumstances TGF-f31 was more abundant than
TGF-/32 or TGF-133. Symbols are: (El) UUO; (El) UUO + Los.
tide-i (MCP-1) mRNAs in tubule epithelium in the obstructed,
but not the contralateral or sham kidneys, followed the same time
frame (12 hr) after UUO and gradually rose and stayed high at 1,
2, and 4 days, in parallel with the increase in cortical interstitial
macrophages. Moreover, a strong correlation between the cortical
macrophage cell number and TGF-131 mRNA relative levels was
found, suggesting that these immune cells may also modulate the
sequence of events culminating in interstitial fibrosis in this
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condition. Many studies have shown that TGF-p is secreted by
virtually all cell types in a biologically inactive form [361,but it is
unknown whether infiltrating (macrophages) induce native kidney
cells to synthesize and secrete TGF-J31 in UUO.
We did not design our experiments to determine the role of
infiltrating macrophages in the local generation of TGF-13. Nev-
ertheless, at 24 hours post-obstruction we consistently found
TGF-131-immunoreactive mononuclear cells in the interstitium of
obstructed kidneys but not in the interstitium of losartan-treated
UUO kidneys. It seems, therefore, that these cells may express
and secrete the cytokine and thus contribute to at least part of the
immunoreactivity detected in the interstitium at both 24 hours
and 7 days, and to the renal damage characteristic of UUO.
Immunohistochemical techniques have shown that in the nor-
mal adult mouse kidney, TGF-f31 is expressed primarily in distal
tubule cells and the staining is confined to the cortex; in contrast,
TGF-p2 is present in JGA cells [34]. Our results suggest that acute
and chronic UUO shift TGF-13 immunoreactive content to the
interstitium of outer medulla and perivascular space. In view of
the changes in interstitial distribution of TGF-13, our findings
suggest that in response to ureteral occlusion, fibroblasts and/or
macrophages as well as tubule epithelial and/or vascular smooth
muscle cells may produce and secrete TGF-f3 which would
stimulate local ECM synthesis leading to renal fibrosis. Kaneto et
al [11] using PCR reported that TGF-/31 mRNA levels from
isolated renal tubules but not from isolated glomeruli were
significantly increased in kidneys obstructed for 5 days. Our
finding of increased TGF-J31, and also /32 and f33, immunoreactiv-
ity in tubular epithelial cells in kidneys obstructed for 24 hours,
provides further evidence that native kidney cells may play an
important role in the development of interstitial fibrosis in UUO.
The possibility that distention or increased tubule pressure acts
by itself or in concert with Ang II to induce TGF-f3, tubule
MCP-1, activation and attraction of macrophages and other
immune response cells remains to be tested. The precise role of
the interstitial mononuclear cell infiltrate in UUO is unknown,
but the studies already quoted [11, 12] and those of others [37, 38]
leave no doubt that these cells play an important role in the
pathogenesis of the renal damage induced by UUO. Equally
unknown at present is the role of Ang II in the alteration and
overproduction of ECM by infiltrating or resident cells, which
would be eventually responsible for the induction of interstitial
fibrosis in UUO. Nevertheless, our results and those of Kaneto et
al [39] raise the possibility that Ang II may modulate TGF-J3
production in infiltrating mononuclear cells in UUO.
In conclusion, TGF-f3 is up-regulated at the transcriptional
level in UUO and its isoforms differentially regulated as a
function of the duration of the obstruction, the area of the kidney,
the portion of the nephron and the cellular type involved. TGF-/31
is also expressed by infiltrating mononuclear cells in acute UUO.
While the precise mechanism is unclear, increased local produc-
tion of Ang II, possibly as a result of high renal pressure or stretch
on the tubules and vessels of the kidney, may directly or indirectly
initiate TGF-/3 expression. Some of the functional and structural
changes of UUO may be partially reversible by blockade of the
renin-angiotensin system. Ang II is a potent stimulus for the local
production of substances that directly and indirectly lead to
fibrosis.
Acknowledgments
This study was supported by a VA Merit Review Grant and RO1-DK
30201. Dr. Angel Montero is a Research Fellow supported by the
Ministerio Espanol de Educación y Ciencia. Losartan was a gift of E. I.
DuPont de Nemours & Co., Wilmington, Delaware, USA. Part of this
work was presented in preliminaiy form at the 26th annual meeting of the
American Society of Nephrology, Boston, November 14 to 17, 1993.
Reproduction of Figure 6 in color was sponsored by Merck Pharmaceu-
ticals. We are grateful to Ms. Rosemarie Kobau for her administrative
assistance.
Reprint requests to Manuel MartInez-Maldonado, MD., Medical Service
(111), Atlanta VA Medical Center, 1670 Clairmont Rd., Decatur, Georgia
30033, USA.
References
1. NAGLE RB, JOHNSON ME, HERVIS HR: Proliferation of renal inter-
stitial cells following injury induced by ureteral obstruction. Lab Invest
35:18—22, 1976
2. VAUGHAN ED JR, SORENSEN EJ, GILLENWATER JY: The renal hemo-
dynamic response to chronic unilateral complete ureteral occlusion.
Invest Urol 8:78—90, 1970
3. NAGLE RB, BULGER RE, CUTFER RE, JERVIS HR, BENDITIT EP:
Unilateral obstructive nephropathy in the rabbit: I. Early morpho-
logic, physiologic and histochemical changes. Lab Invest 28:456—467,
1973
4. NAGLE RB, BULGER RE, CUTTER RE, JERvIs HR, BENDITF EP:
Unilateral obstructive nephropathy in the rabbit: II. Late morphologic
changes. Lab Invest 38:270—278, 1978
5. KLAHR 5, PURKERSON ML: The pathophysiology of obstructive ne-
phropathy: The role of vasoactive compounds in the hemodynamic
and structural abnormalities of the obstructive kidney. Am J Kidney
Dis 23:219—233, 1994
6. ONG ACM, FINE LG: Tubule-derived growth factors and cytokines in
the pathogenesis of tubulointerstitial fibrosis: Implications for human
renal disease progression. Am J Kidney Dis 23:205—209, 1994
7. WALTON G, BUTrYAN R, GARCIA-MONTES E, OL5sON CA, HENSLE
TW, SAWCZUK IS: Renal growth factor expression during the early
phase of experimental hydronephrosis. J Urol 148:510—514, 1992
8. SHARMA AK, MAUER SM, KIM Y, MICHAEL AF: Interstitial fibrosis in
obstructive nephropathy. Kidney mt 44:774—788, 1993
9. KUNCIO GS, NEHsoN EG, HAVERTY T: Mechanisms of tubulointer-
stitial fibrosis. Kidney mt 39:550—556, 1991
10. ROBERTS AB, HEINE UI, FLANDERS KC, SPORN MB: Transforming
growth factor-/3: Major role in regulation of extracellular matrix. Ann
NYAcad Sci 580:225—232, 1990
11. KANETO H, MORRI5SEY J, KLAI-IR S: Increased expression of TGF-131
mRNA in the obstructed kidney of rats with unilateral ureteral
ligation. Kidney mt 44:313—321, 1993
12. DIAMOND JR, KEES-FOLTS D, DING G, FRYE JE, RESTREPO NC:
Macrophages, monocyte chemoattractant peptide-1, and TGF-131 in
experimental hydronephrosis. Am J Physiol 266 (Renal Fluid Electrol
Physiol 35):F926—F933, 1994
13. PIMENTEL JL JR, MART1NEZ-MALDONADO M, WILCOX JN, WANG S,
Luo C: Regulation of renin-angiotensin system in unilateral ureteral
obstruction. Kidney mt 44:390—400, 1993
14. PIMENTEL JL JR, WANG S. MARTiNEZ-MALDONADO M: Regulation of
the renal angiotensin II receptor gene in acute unilateral ureteral
obstruction. Kidney mt 45:1614—1621, 1994
15. EL-DANR SS, GEE J, DIEP S, HANSS BG, VARI R, CHA0 J: Upregula-
tion of renin-angiotensin system and downregulation of kallikrein in
obstructive nephropathy. Am J Physiol 264(33):F874—F881, 1993
16. SAMBFII MP, SWAMINATHAN N, WANG H, RONG H: Increased EGF
binding and EGFR mRNA expression in rat aorta with chronic
administration of pressor angiotensin II. Biochem Med Metab Biol
48:8—18, 1992
17. GIBBONS GH, PItxvr RE, DZAU VJ: Vascular smooth muscle cell
hypertrophy vs. hyperplasia: Autocrine transforming growth factor-p3
expression determines growth response to angiotensin II. J Clin Invest
90:456—461, 1992
1246 Pimentel et a!: TGF-/3 in obstntctive nephropathy
18. WOLF G, KILLEN PD, NEII.soN EG: Intracellular signaling of tran-
scription and secretion of type IV collagen after angiotensin II-
induced cellular hypertrophy in cultured proximal tubule cells. Mol
Biol Cell 2:219—227, 1991
19. JOHNSON RJ, ALPERS CE, YosHIMuI A, LOMBARDI D, PRITZL P,
FLOEGE J, SCHWARTZ SM: Renal injuly from angiotensin Il-mediated
hypertension. Hypertension 19:464—474, 1992
20. THOMPSON NL, FLANDERS KC, SMITH JM, ELLINGSWORTH LR, ROB-
ERTS AB, SPORN MB: Expression of transforming growth factor-/Il in
specific cells and tissues of adult and neonatal mice. J Cell Biol
108:661—669, 1989
21. CHIRGWIN JJ, PRZBYLA AE, MACDONALD RJ, RUrFER WJ: Isolation
of biologically active ribonucleic acid from sources enriched in
ribonuclease. Biochemistty 18:5294—5299, 1979
22. HUMES HD, NAKAMURA T, CIEsLINsKI DA, MILLER D, EMMONS RV,
BORDER WA: Role of proteoglycans and cytoskeleton in the effects of
TGF /31 on renal proximal tubule cells. Kidney mt 43:575—584, 1993
23. IGNOTZ R, MASSAGUE J: Transforming growth factor-fl stimulates the
expression of fibronectin and collagen and their incorporation into the
extracellular matrix. J Biol Chem 261:4337—4345, 1986
24. IGNOTZ R, END0 T, MASSAGU J: Regulation of fibronectin and type
I collagen mRNA levels by transforming growth factor- /3. J Biol Chem
261:6443—6446, 1987
25. CREELY JJ, Diat.io SI, HOWE AM, HARALSON MA: Effects of
transforming growth factor-/I on collagen synthesis by normal rat
kidney epithelial cells. Am I Pathol 140:45—55, 1992
26. LAIHO M, SAKSELA 0, ANDREASEN PA, KEslu-OJA I: Enhanced
production and extracellular deposition of the endothelial-type plas-
minogen activator inhibitor in cultured human lung fibroblasts by
transforming growth factor-beta. J Cell Biol 103:2403—2410, 1986
27. EDWARDS DR, MURPHY G, REYNOLDS JJ, WHITMAN SE, DOCHERTY
AJP, ANGEL P. HEATH JK: Transforming growth factor beta modu-
lates the expression of collagenase and metalloproteinase inhibitors.
EMBO J 6:1899—1904, 1987
28. POSTLETHWAITE AE, KESKI-OJA J, MOSES HL, KANG AH: Stimulation
of the chemotactic migration of human fibroblasts by transforming
growth factor /3. J Exp Med 165:251—256, 1987
29. WAHL SM, HUNT DA, WAKEFIELD LM, MCCARNEY-FRANCIS N,
WAHL LM, ROBERTS AB, SPORN MB: Transforming growth factor
type /3 induces monocyte chemotaxis and growth factor production.
Proc Nat! Acad Sci USA 84:5788—5792, 1987
30. BORDER WA, NOBLE NA, YAMAMOTO T, HARPER JR, YAMAGUCHI Y,
PIERSCHBACHER MD, RUOSLAHTI E: Natural inhibitor of transforming
growth factor-fl protects against scarring in experimental kidney
disease. Nature 360:361—364, 1992
31. Bs.to YJ, KIM Si, DANIELPOUR D, O'REILLY MA, KIM KY, TREPEL
JB: Cyclic AMP induces TGF-/32 gene expression and growth arrest in
the human androgen-independent prostate carcinoma cell line PC-3.
Proc Nat! Acad Sci USA 89:3556—3560, 1992
32. MULHERON GW, DANIELPOUR D, SCHOMBERG DW: Rat thecal/
interstitial cells express TGF/3- type 1 and 2, only type 2 is regulated
by gonadotropin in vitro. Endocrinology 129:368—374, 1991
33. MACKAY K, KONDAIAH P, DANIELPOUR D, AUSTIN HA, BROWN PD:
Expression of transforming growth factor fIt and f32 in rat glomeruli.
Kidney mt 38:1095—1100, 1990
34. HomioSw S, MCCUNE BK, R.AY PE, Ko JB, SPORN MB, KLOTMAN
PE: Water deprivation stimulates transforming growth factor-/32
accumulation in the juxtaglomerular apparatus of mouse kidney. J
Clin Invest 88:2117—2122, 1991
35. ANTONIPILLAI I, HOANG LE T, SOCENEANTU L, HORTON R: Trans-
forming growth factor-/I is a renin secretagogue at picomolar concen-
trations. Am J Physiol 265(34):F537—F541, 1993
36. BORDER WA, NOBLE NA: Transforming growth factor /3 in tissue
fibrosis. NEnglJMed 331:1286—1292, 1994
37. SCHREINER GF, HARRIS KPG, PURKERSON ML, KLAHR S: Immuno-
logical aspects of acute ureteral obstruction: Immune cell infiltrate in
the kidney. Kidney mt 34:487—493, 1988
38. R0VIN BH, HARRIS KPG, MORRISON A, KLAI-IR S, SCHREINER GF:
Renal cortical release of a specific macrophage chemoattractant in
response to ureteral obstruction. Lab Invest 63:213—220, 1990
39. KANETO H, MORRISSEY J, MCCRACKEN R, REYES A, KLAHR S:
Enalapril reduces collagen type IV synthesis and expansion of the
interstitium in the obstructed rat kidney. Kidney mt 45:1637—1647,
1994
